Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms (N-methyl-(11C))2-(4'-methylaminophenyl)-6-hydroxybenzothiazole, 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole, FSA-PIB AD + [4] |
Target |
Action inhibitors |
Mechanism APP inhibitors(Beta amyloid A4 protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC14H12N2OS |
InChIKeyZQAQXZBSGZUUNL-BJUDXGSMSA-N |
CAS Registry566170-04-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Pittsburgh Compound B | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis | Phase 2 | United States | 10 Jul 2023 | |
Alzheimer Disease | Phase 2 | United States | 01 Mar 2009 | |
Alcohol Use Disorder | Phase 1 | United States | 01 Dec 2018 | |
Posterior cortical atrophy syndrome | Phase 1 | United States | 01 Nov 2012 | |
Aphasia, Broca | Phase 1 | United States | 01 Mar 2010 | |
Primary Progressive Nonfluent Aphasia | Phase 1 | United States | 01 Mar 2010 |
Not Applicable | - | [18F]Florbetazine (FBZ) | psrgxwjyuh(mubvdvloga) = uxawtmcpuq kdhjcvahmc (ncxwynotbr ) View more | - | 04 Apr 2025 | ||
Phase 2 | 89 | (Alzheimer's Disease) | ioefllyxaj(opqvncwlnf) = iuknqfmolz axxfzcfodw (vtatpakgnu, 0.53) View more | - | 01 Nov 2016 | ||
(Cognitive Normal Elderly) | ioefllyxaj(opqvncwlnf) = tklgafydhe axxfzcfodw (vtatpakgnu, 0.28) View more |